Study identification

EU PAS number

EUPAS1000000686

Study ID

1000000686

Official title and acronym

Real-world evidence of first-line Osimertinib effectiveness in Bulgarian patients: a retrospective analysis

DARWIN EU® study

No

Study countries

Bulgaria

Study description

Real-World Data Analysis of First-Line Osimertinib Compared to Clinical Trials Using Danny Platform

Study status

Finalised
Research institutions and networks

Institutions

National Council on Prices and Reimbursement of Medicinal Products (NCPRMP), Bulgaria

Contact details

Alexandra Savova

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
No external funding
Regulatory

Was the study required by a regulatory body?

Unknown

Is the study required by a Risk Management Plan (RMP)?

Not applicable